OncoMatch/Clinical Trials/NCT06084806
Test-retest Evaluation of [18F]F-AraG PET
Is NCT06084806 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies [18F]F-ARAG PET for non-small cell lung cancer.
Treatment: [18F]F-ARAG PET — This pilot study aims to evaluate the test-retest variability of \[18F\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \[18F\]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore these objectives, eligible subjects will undergo two \[18F\]F-AraG PET/CT scans within 7 days of each other prior to receiving treatment. This study is a single-site, open-label, non-randomized, single-arm pilot trial. Patients and care providers will not be blinded to any part of the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
candidate to receive immunotherapy as monotherapy or as combination therapy for advanced/metastatic disease
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Iowa Hospitals and Clinics · Iowa City, Iowa
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify